HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Online-Only Appendix Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Juutilainen, A. Articles by Laakso, M. Search for Related Content PubMed PubMed Citation Articles by Juutilainen, A. Articles by Laakso, M. Social Bookmarking                What's this?

Type 2 Diabetes as a "Coronary Heart Disease Equivalent"

An 18-year prospective population-based study in Finnish subjects

¹ Department of Medicine, University of Kuopio, Kuopio, Finland
² Department of Medicine, University of Turku, Turku, Finland

Address correspondence and reprint requests to Markku Laakso, MD, Academy Professor, University of Kuopio and Kuopio University Hospital, Department of Medicine, 70210 Kuopio, Finland. E-mail: markku.laakso{at}kuh.fi

	ABSTRACT

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS APPENDIX References

 
OBJECTIVE—The purpose of this study was to investigate the hypothesis that coronary heart disease (CHD) mortality in diabetic subjects without prior evidence of CHD is equal to that in nondiabetic subjects with prior myocardial infarction or any prior evidence of CHD.

RESEARCH DESIGN AND METHODS—During an 18-year follow-up total, cardiovascular disease (CVD) and CHD deaths were registered in a Finnish population-based study of 1,373 nondiabetic and 1,059 diabetic subjects.

RESULTS—Adjusted multivariate Cox hazard models indicated that diabetic subjects without prior myocardial infarction, compared with nondiabetic subjects with prior myocardial infarction, had a hazard ratio (HR) of 0.9 (95% CI 0.6–1.5) for the risk of CHD death. The corresponding HR was 0.9 (0.5–1.4) in men and 1.9 (0.6 –6.1) in women. Diabetic subjects without any prior evidence of CHD (myocardial infarction or ischemic electrocardiogram [ECG] changes or angina pectoris), compared with nondiabetic subjects with prior evidence of CHD, had an HR of 1.9 (1.4–2.6) for CHD death (men 1.5 [1.0–2.2]; women 3.5 [1.8–6.8]). The results for CVD and total mortality were quite similar to those for CHD mortality.

CONCLUSIONS—Diabetes without prior myocardial infarction and prior myocardial infarction without diabetes indicate similar risk for CHD death in men and women. However, diabetes without any prior evidence of CHD (myocardial infarction or angina pectoris or ischemic ECG changes) indicates a higher risk than prior evidence of CHD in nondiabetic subjects, especially in women.

Abbreviations: CHD, coronary heart disease • CVD, cardiovascular disease • ECG, electrocardiogram • WHO, World Health Organization

	INTRODUCTION

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS APPENDIX References

 
Type 2 diabetes increases the risk of coronary heart disease (CHD) events at least by two- to threefold in type 2 diabetic subjects compared with nondiabetic subjects (1). In type 2 diabetic women the relative risk is even greater (2). The reasons for this increased risk are largely unknown but could be related at least in part to more adverse changes in cardiovascular risk factors among diabetic women compared with diabetic men. Although the incidence of CHD events in nondiabetic subjects has considerably decreased during the last decades, this is not true for type 2 diabetic patients, particularly for women (3).

We previously reported that type 2 diabetic patients without a history of prior myocardial infarction have the same risk of CHD death as nondiabetic subjects with a history of prior myocardial infarction (4). This observation has led to the conclusion that type 2 diabetes is a CHD equivalent and has had a profound effect, particularly on the recommendations for treatment of dyslipidemia (5).

During recent years other studies have investigated the same question in different populations and study settings. Contradictory results have been obtained, with some studies confirming our original findings (6–10) and some studies reporting opposite results, especially among men (11–18). The conclusion of these studies is that type 2 diabetes might be a CHD equivalent, but only among women.

Our original study population included 1,059 patients with type 2 diabetes and 1,373 nondiabetic subjects, who were followed for up to 7 years (4). The limitation of our original study was that the number of CHD deaths during the follow-up was relatively low. Furthermore, data analysis was not done separately for men and women, and myocardial infarction was the only criterion used for CHD.

Because of contradictory data from other studies, we have prolonged the follow-up of our cohort to up to 18 years using mortality from CHD, cardiovascular disease (CVD), and all causes as end points. Furthermore, we have analyzed the results separately for men and women, and, in addition to a prior history of myocardial infarction, we have applied other criteria for the presence of CHD at baseline.

	RESEARCH DESIGN AND METHODS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS APPENDIX References

 
A detailed description of study participants has been published previously (4). A random sample of 1,373 nondiabetic subjects (638 men and 735 women) and 1,059 type 2 diabetic subjects (581 men and 478 women) participated in the baseline study carried out in 1982–1984. All subjects were aged 45–64 years, and they were born and living in the Turku University Hospital district in West Finland and in the Kuopio University Hospital district in East Finland. The random sample of nondiabetic subjects was taken from the population register, and type 2 diabetic subjects were identified through a national drug reimbursement register. The mean age was 54.6 years in nondiabetic men, 54.8 years in nondiabetic women, 57.3 years in diabetic men, and 59.1 year in diabetic women.

Baseline study
The study program was carried out during one outpatient visit at the Clinical Research Unit of the University of Kuopio or the Rehabilitation Research Centre of the Social Insurance Institution in Turku as previously described (19). The visit included an interview on the history of chest pain suggestive of CHD, smoking, alcohol intake, physical activity, and the use of drugs. All medical records of subjects who reported in an interview that they had been admitted to the hospital for chest pain symptoms were reviewed. Review of the medical records was performed by two of us (M.L. in Kuopio and T.R. in Turku) after a careful standardization of the methods between the reviewers. Hospital records of those participants who reported that they had been hospitalized for CVD were reviewed. Modified World Health Organization (WHO) criteria for definite or possible myocardial infarction, based on chest pain symptoms, electrocardiogram (ECG) changes, and cardiac enzymes were used to verify the diagnosis of previous myocardial infarction (20). Subjects were classified as having hypertension if they were receiving drug treatment for hypertension or if systolic blood pressure was 160 mmHg or diastolic blood pressure was 95 mmHg in the sitting position after a 5-min rest. Standing height and body weight were measured. In all statistical analyses, subjects were classified as nonsmokers or current smokers. At baseline 86 (13.5%) of the nondiabetic men, 113 (15.4%) of the nondiabetic women, 250 (43.0%) of the diabetic men, and 271 (56.7%) of the diabetic women were receiving drug treatment for hypertension. Only 7 diabetic men, 2 diabetic women, and 2 nondiabetic subjects were receiving drug treatment for hyperlipidemia. Of the diabetic subjects, 92 (15.8%) men and 55 (11.5%) women were treated with diet only, 410 (70.6%) men and 352 (73.6%) women with oral hypoglycemic drugs but not with insulin, and 79 (13.6%) men and 70 (14.6%) women with insulin. The Rose classification was used to evaluate the presence of typical angina pectoris, and Whitehall changes according to Minnesota coding were used to identify ischemic changes on the ECG (21).

Classification of prior evidence of CHD
Four categories of prior evidence of CHD were defined: 1) prior myocardial infarction verified at the hospital, 2) angina pectoris, 3) ischemic ECG changes, and 4) any prior evidence of CHD (myocardial infarction or angina pectoris or ischemic ECG changes).

Biochemical methods
All laboratory specimens were taken after a 12-h fast at 0800. The methods for the determination of HbA₁, serum total cholesterol, triglycerides, HDL cholesterol, and plasma glucose have been previously reported (19).

Follow-up study
The follow-up period lasted until 1 January 2001. Information on the vital status of the participants and copies of death certificates of all deceased subjects were obtained from the Cause-of-Death Register (Statistics Finland). In the final classification of causes of death, hospital records and autopsy records, if available, also were used. The causes of death were reviewed by A.J. and S.L. The end points used in this study were total, cardiovascular (codes 390–459), and CHD death (codes 410–414) according to the ICD-8.

Statistical methods
Data analyses were conducted with the SPSS 11.5.1 programs (SPSS, Chicago, IL). The results for continuous variables are given as means ± SD and for categorical variables as percentages. Logarithmic transformation was used for triglycerides. The differences in the cumulative survival between the groups were studied by Kaplan-Meier estimates, with log-rank test statistics. Multivariate Cox regression models were used to examine the association of cardiovascular risk factors with the end points. The Mantel-Haenszel test was applied to evaluate homogeneity between nondiabetic and diabetic subjects in the association of a prior history of CHD with CHD mortality, when different definitions of prior CHD were used.

Approval of the ethics committees
The Ethics Committees of the Kuopio University Hospital and the Turku University Central Hospital approved the study. All study subjects gave informed consent.

	RESULTS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS APPENDIX References

 
Table 1 shows the number of subjects (with the percentage in parentheses) who had prior evidence of CHD and who died during the follow-up by sex for nondiabetic and diabetic subjects. The median follow-up was 17.5 years with a total of 34,753 patient-years. During this period, 199 (31.2%) nondiabetic men, 98 (13.3%) nondiabetic women, 423 (72.8%) diabetic men, and 345 (72.2%) diabetic women died. Altogether 76 (11.9%) nondiabetic men, 17 (2.3%) nondiabetic women, 221 (38.0%) diabetic men, and 156 (32.6%) diabetic women died of CHD.

Figure 1 shows Kaplan-Meier curves for CHD death during the 18-year follow-up in nondiabetic subjects and diabetic subjects with and without prior myocardial infarction or CHD. Diabetic subjects without prior myocardial infarction had a similar risk for CHD death as nondiabetic subjects with prior myocardial infarction when the sexes were analyzed together. However, when sexes were analyzed separately, the relative risk of CHD death for diabetic subjects without myocardial infarction, compared with that for nondiabetic subjects with myocardial infarction, was somewhat higher in women than in men. When the criteria were any prior evidence of CHD, diabetes was a stronger risk factor for CHD death when the sexes were analyzed together (Fig. 1). The presence of diabetes had a larger effect on CHD mortality in both men and women compared with that in nondiabetic subjects with any prior evidence of CHD.

View larger version (26K): [in this window] [in a new window]   Figure 1— CHD mortality. Kaplan-Meier estimates of CHD death during an 18-year follow-up according to the status of diabetes (DM) and prior evidence of CHD. Prior myocardial infarction (MI) is presented in the left-hand panel and prior CHD, defined as Whitehall changes of ECG, typical angina pectoris by the Rose classification, or prior myocardial infarction, in the right-hand panel in combination with the status of diabetes in men (n = 1,219), in women (n = 1,213), and in all (n = 2,432).

The results for CVD and total mortality were quite similar to those for CHD mortality. In contrast, diabetes status was a stronger predictor for non-CVD mortality compared with prior CHD in men but not in women.

The interaction "diabetes status x previous myocardial infarction" was studied in Cox models after adjustment for age, sex, area of residence, current smoking, and total cholesterol. A significant interaction was observed with P = 0.001 for CHD death and 0.004 for CVD death. The Mantel-Haenszel test was applied to evaluate subgroup homogeneity between nondiabetic and diabetic subgroups. The results were significant (P < 0.01) in all subjects and in men and women, regardless of the definition used for prior CHD, demonstrating heterogeneity in the association of prior CHD with CHD mortality among nondiabetic and diabetic subjects.

	CONCLUSIONS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS APPENDIX References

 
Our study indicates that type 2 diabetes is a CHD equivalent during an 18-year follow-up, when the criterion for CHD is prior myocardial infarction. However, with respect to other definitions of CHD, including angina pectoris, ischemic ECG changes, or any evidence of prior CHD (myocardial infarction or angina pectoris or ECG changes), the prognosis for subjects with type 2 diabetes without prior CHD was worse than that for nondiabetic subjects with prior CHD, particularly for women. This indicates that the use of a prior myocardial infarction as a criterion for CHD underestimates the significance of diabetes status with respect to mortality from CHD. The relative effect of the simultaneous presence of diabetes and prior CHD was particularly detrimental among women. Finally, in men but not women, diabetic subjects without prior evidence of CHD (with the exception of prior myocardial infarction) had significantly higher non-CVD mortality compared with that in nondiabetic subjects with prior evidence for CHD.

Contradictory findings have been reported in studies investigating the predictive value of prior myocardial infarction or diabetes on the risk of subsequent CHD events. Previous studies have been very heterogeneous, particularly with respect to sex, and have included men only (11,13,17), women only (10), or both sexes (4,8,9,12,14–16,18). Because there is a sex difference in diabetic subjects in the risk of CHD, it is important that the results are analyzed separately for both sexes. Furthermore, the age range has been variable, including relatively young (25–44 years) and old (65–85 years) subjects, making the comparison between the studies difficult, because diabetes is a considerably weaker risk factor for CHD death in elderly individuals (11,17).

In several studies in which CHD mortality has been analyzed separately in men and women, the effect of diabetes status, compared with the effect of prior CHD, has been greater in women than in men (8,9,14,15,18). This is not surprising because women with diabetes lose their relative protection against cardiovascular complications (2,24,25). A high relative risk of CHD mortality among type 2 diabetic women could be also due to the superior survival of women without diabetes (26). Finally, some studies have reported that a long duration of diabetes increases further the risk of CHD death (9,10,13,17).

Our original observation that type 2 diabetes is a "CHD equivalent" was based on a 7-year follow-up of nondiabetic and diabetic subjects (4). The baseline study was conducted in 1982–1984, and there is a possibility that drug treatments started during the follow-up could have modified the prognosis of these patients. In the beginning of 1990s effective cardiovascular drug treatments, including the use of statins and ACE inhibitors, were introduced, as well as ß-blocker treatment and thrombolysis for patients suffering from an acute myocardial infarction. However, these treatment modalities are not likely to have a substantial effect on the prognosis of subjects included in this follow-up study, given the shape of the mortality curves reported in Fig. 1. Although there is some "leveling off effect" of the mortality curves in diabetic patients, the effects of these new treatment modalities to improve prognosis of the patients, if any, is very hard to demonstrate. This may indicate that the treatment of diabetic patients, being relatively unchanged during the first 10 years of the follow-up, has not changed the prognosis during the longer follow-up.

Our study has several strengths. The numbers of diabetic and nondiabetic subjects were large, and the follow-up period was long. The diagnosis of type 2 diabetes was based on a previous history of diabetes, laboratory examinations at the baseline study, and C-peptide measurement among insulin-treated diabetic patients. Therefore, it is highly unlikely that our study cohort included patients with type 1 diabetes. This careful differentiation of the types of diabetes has not been performed in any of the other studies (6–18). In contrast, the diagnosis of type 2 diabetes has been based on a reported history of diabetes in most of the studies (8–11,13,17). Furthermore, we evaluated CHD at baseline according to the WHO criteria, but this has not been systematically done in any of the other studies (8–18). Therefore, it is possible that classification errors have occurred in other studies with respect to the diagnosis of type 2 diabetes and CHD events. These possible errors may in part explain the discrepant findings.

In summary, we have demonstrated that type 2 diabetes is a "CHD equivalent" in an 18-year follow-up study of Finnish subjects, if prior myocardial infarction was used to define CHD. When less stringent criteria for prior CHD were used (myocardial infarction or ischemic ECG changes or angina pectoris), type 2 diabetes carried a larger risk than prior CHD, especially in women. These findings emphasize the need for active management of cardiovascular risk factors in the prevention of CHD in type 2 diabetic subjects, particularly in women.

	APPENDIX

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS APPENDIX References

 

Appendix Table 1— The effect of age, duration of diabetes, and the metabolic syndrome on the equivalence of risks associated with type 2 diabetes and prior myocardial infarction

All subjects Men Women HR (95% CI) P HR (95% CI) P HR (95% CI) P CHD death     Age below median (<56.9 years) 0.96 (0.47–1.96) 0.905 0.86 (0.39–1.89) 0.700 1.67 (0.21–13.24) 0.627     Age above median (56.9 years) 1.00 (0.57–1.72) 0.988 0.81 (0.43–1.52) 0.511 2.14 (0.52–8.85) 0.294     Diabetes duration below median (<8 years) 1.00 (0.63–1.60) 0.990 0.96 (0.56–1.63) 0.880 1.78 (0.53–5.94) 0.352     Diabetes duration above median (8 years) 0.91 (0.58–1.43) 0.674 0.71 (0.42–1.19) 0.193 2.06 (0.64–6.66) 0.228     No metabolic syndrome 0.99 (0.55–1.77) 0.968 0.83 (0.44–156) 0.559 3.52 (0.47–26.16) 0.220     Metabolic syndrome 0.67 (0.34–1.30) 0.233 0.71 (0.32–1.56) 0.392 0.73 (0.17–3.11) 0.667 CVD death     Age below median (<56.9 years) 1.17 (0.60–2.28) 0.638 0.91 (0.44–1.89) 0.797 2.98 (0.40–22.45) 0.290     Age above median (56.9 years) 1.24 (0.73–2.09) 0.421 1.06 (0.59–1.91) 0.845 2.85 (0.70–11.67) 0.146     Diabetes duration below median (<8 years) 1.24 (0.80–1.92) 0.327 1.08 (0.66–1.77) 0.765 2.73 (0.84–8.84) 0.094     Diabetes duration above median (8 years) 1.17 (0.76–1.78) 0.479 0.88 (0.54–1.42) 0.593 2.96 (0.93–9.49) 0.067     No metabolic syndrome 1.33 (0.75–2.34) 0.330 1.10 (0.59–2.05) 0.759 5.34 (0.73–38.92) 0.098     Metabolic syndrome 0.79 (0.43–1.45) 0.449 0.69 (0.34–1.38) 0.295 1.25 (0.30–5.19) 0.758

HRs comparing diabetic subjects without prior myocardial infarction with nondiabetic subjects with prior myocardial infarction were calculated from Cox models for CHD mortality and CVD mortality, adjusted for age, sex (all subjects), area of residence, smoking status, hypertension, total cholesterol, HDL cholesterol, and logarithm of triglycerides.

	Footnotes

 
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

Received for publication July 22, 2005. Accepted for publication September 8, 2005.

	References

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS APPENDIX References

 

1. Laakso M: Diabetes and cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med249 :225 –235,2001[Medline]
   
2. Juutilainen A, Kortelainen S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care27 :2898 –2904,2004[Abstract/Free Full Text]
   
3. Gu K, Cowie CC, Harris MI: Diabetes and decline in heart disease mortality in US adults. JAMA281 :1291 –1297,1999[Abstract/Free Full Text]
   
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med339 :229 –234,1998[Abstract/Free Full Text]
   
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106 :3143 –3421,2002[Free Full Text]
   
6. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med342 :145 –153,2000[Abstract/Free Full Text]
   
7. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A: Impact of diabetes on long-term prognosis in patients with unstable angina pectoris and non-Q-wave myocardial infarction. Circulation102 :1014 –1019,2000[Abstract/Free Full Text]
   
8. Mukamal KJ, Nesto RW, Cohen MC, Muller JE, Maclure M, Sherwood JB, Mittleman MA: Impact of diabetes on long-term survival after acute myocardial infarction. Diabetes Care24 :1422 –1427,2001[Abstract/Free Full Text]
   
9. Natarajan S, Liao Y, Sinha D, Cao G, McGee DL, Lipsitz SR: Sex differences in the effect of diabetes duration on coronary heart disease mortality. Arch Intern Med165 :430 –435,2005[Abstract/Free Full Text]
   
10. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med161 :1717 –1723,2001[Abstract/Free Full Text]
    
11. Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE: Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med161 :242 –247,2001
    
12. Evans JM, Wang J, Morris AD: Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ324 :939 –942,2002[Abstract/Free Full Text]
    
13. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB: The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. Am Coll Cardiol40 :954 –960,2002[Abstract/Free Full Text]
    
14. Becker A, Bos G, de Vegt F, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer, CDA: Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease: 10-year follow-up of the Hoorn Study. Eur Heart J24 :1406 –1413,2003[Abstract/Free Full Text]
    
15. Natarajan S, Liao Y, Cao G, Lipsitz SR, McGee DL: Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med163 :1735 –1740,2003[Abstract/Free Full Text]
    
16. Lee CD, Folsom AR, Pankow JS, Brancati FL: Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation109 :855 –860,2004[Abstract/Free Full Text]
    
17. Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J: Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med164 :1438 –1443,2004[Abstract/Free Full Text]
    
18. Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J: Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with and without history of myocardial infarction. Diabetologia48 :656 –661,2005
    
19. Laakso M, Rönnemaa T, Pyörälä K, Kallio V, Puukka P, Penttilä I: Atherosclerotic vascular disease and its risk factors in non-insulin-dependent and nondiabetic subjects in Finland. Diabetes Care11 :449 –463,1988[Abstract]
    
20. World Heath Organization: Proposal for the Multinational Monitoring of Trends and Determinants in Cardiovascular Disease and Protocol (MONICA Project). WHO/MNC/82.1, Rev 1. Geneva, World Health Org.,1983
    
21. Rose G, Blackburn H, Gillum RF, Prineas RJ: Cardiovascular Survey Methods. 2nd ed. Geneva, World Health Org.,1982
    
22. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation110 :1251 –1257,2004[Abstract/Free Full Text]
    
23. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med164 :1066 –1076,2004
    
24. Barrett-Connor EL, Cohn BA, Wingard DL, Cohn BA, Edelstein SL: Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernado Study. JAMA265 :627 –631,1991[Abstract]
    
25. Hu G, the DECODE Study Group: Gender difference in all-cause and cardiovascular mortality related to hyperglycemia and newly-diagnosed diabetes. Diabetologia46 :608 –617,2003[Medline]
    
26. Lee WL, Cheung AM, Cape D, Zinman B: Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care23 :962 –968,2000[Abstract]
    

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				T. K. Schramm, G. H. Gislason, L. Kober, S. Rasmussen, J. N. Rasmussen, S. Z. Abildstrom, M. L. Hansen, F. Folke, P. Buch, M. Madsen, et al. Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People Circulation, April 15, 2008; 117(15): 1945 - 1954. [Abstract] [Full Text] [PDF]

				A. C. Dale, T. I. Nilsen, L. Vatten, K. Midthjell, and R. Wiseth Diabetes mellitus and risk of fatal ischaemic heart disease by gender: 18 years follow-up of 74 914 individuals in the HUNT 1 Study Eur. Heart J., December 1, 2007; 28(23): 2924 - 2929. [Abstract] [Full Text] [PDF]

				K. Krzyzanowska, F. Mittermayer, M. Wolzt, and G. Schernthaner Asymmetric Dimethylarginine Predicts Cardiovascular Events in Patients With Type 2 Diabetes Diabetes Care, July 1, 2007; 30(7): 1834 - 1839. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF]

				J. Westerbacka PROactive in Patients With Type 2 Diabetes and Previous Myocardial Infarction: Swinging the Sword of Damocles? J. Am. Coll. Cardiol., May 1, 2007; 49(17): 1781 - 1782. [Full Text] [PDF]

				W. Shu, W. Lei, and S. Peng Recent development of ischaemic heart disease in sex difference Postgrad. Med. J., April 1, 2007; 83(978): 240 - 243. [Abstract] [Full Text] [PDF]

				B. R. Shah, J. E. Hux, and P. C. Austin Diabetes Is Not Treated as a Coronary Artery Disease Risk Equivalent Diabetes Care, February 1, 2007; 30(2): 381 - 383. [Full Text] [PDF]

				Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF]

				R. H. Knopp, M. d'Emden, J. G. Smilde, S. J. Pocock, and on behalf of the ASPEN Study Group Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) Diabetes Care, July 1, 2006; 29(7): 1478 - 1485. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Online-Only Appendix Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Juutilainen, A. Articles by Laakso, M. Search for Related Content PubMed PubMed Citation Articles by Juutilainen, A. Articles by Laakso, M. Social Bookmarking                What's this?